Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06
Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06
复制标题
DOI：
10.1016/s0360-3016(97)00921-8
复制
发表时间：
1998-03-01
影响因子：
7
通讯作者：
Pilepich, MV
中科院分区：
文献类型：
--
作者：
Hanks, GE;Buzydlowski, J;Pilepich, MV
目的：本研究旨在了解经活检证实有淋巴结转移的前列腺癌患者在放射治疗 10 年后没有患癌症。方法和材料：RTOG 方案 #75-06 包括 90 名经活检证实有盆腔淋巴结受累并接受放射治疗的患者。他们自治疗以来一直持续随访，在可行的情况下，从10年临床无癌（无疾病证据，NED）的患者中收集当前前列腺特异性抗原（PSA）水平，以确认治愈，结果：10年生存率为29％，10年临床NED生存率为7％，在5名10年临床NED患者中获得2名PSA水平，他们均低于0.8纳克/毫升，2 已证实治愈的临床分期均为 T-3，格里森评分为 6 和 8，分别有 2 个和 1 个阳性淋巴结，多变量分析显示格里森总和与无病临床生存显着相关，结论：一小部分淋巴结阳性患者在 10 年随访中通过放射治疗治愈（90 例 PSA 中的 2 例，根据临床终点，90 例中 PSA 为 3 例），创新的治疗方案应针对淋巴结阳性患者 努力提高治愈率。 (C) 1998 爱思唯尔科学公司。
Purpose: This study was conducted to see what fraction of prostate cancer patients with biopsy-proven nodes are free of cancer 10 years after radiation treatment,Methods and Materials: RTOG protocol #75-06 included 90 patients with biopsy-proven pelvic nodal involvement treated with radiation. They have been continuously follow-up since treatment, When feasible, current prostate-specific antigen (PSA) levels have been solicited from patients clinically cancer-free (no evidence of disease, NED) at 10 years, to confirm cure,Results: The 10-year survival was 29%, the 10-year clinical NED survival 7%, PSA levels were obtained in 2 of 5 10-year clinical NED patients, they were both less than 0.8 ng/ml, The 2 proven cures were both clinical stage T-3, Gleason Score 6 and 8, and had 2 and 1 positive nodes, respectively, Multivariate analysis showed Gleason sum was significantly associated with clinical survival without disease,Conclusion: A small fraction of node-positive patients are cured at 10-year follow-up by radiation therapy (2 of 90 with PSA +3 of 90 by clinical endpoints), Innovative treatment programs should be directed at node-positive patients in an effort to improve the fraction cured. (C) 1998 Elsevier Science Inc.